Yahoo
OTC Markets OTCQB USD

CytoDyn Inc. (CYDY)

0.2200 -0.0100 (-4.35%)
At close: October 30 at 4:00:00 PM EDT
Chart Range Bar
Loading chart for CYDY
  • Previous Close 0.2300
  • Open 0.2250
  • Bid 0.2214 x 1054500
  • Ask 0.2230 x 1715500
  • Day's Range 0.2171 - 0.2300
  • 52 Week Range 0.1800 - 0.4000
  • Volume 386,293
  • Avg. Volume 1,827,578
  • Market Cap (intraday) 323.294M
  • Beta (5Y Monthly) 1.50
  • PE Ratio (TTM) --
  • EPS (TTM) -0.0300
  • Earnings Date (est.) Jan 14, 2027
  • Forward Dividend & Yield -- (0.00%)
  • Ex-Dividend Date --
  • 1y Target Est --

CytoDyn Inc., a clinical-stage biotechnology company, develops treatments for multiple therapeutic indications. The company develops leronlimab, a novel humanized monoclonal antibody targeting the C-C chemokine receptor type 5 receptor in the areas of COVID-19. Its leronlimab completed phase 2 development for the treatment of micro-satellite stable colorectal cancer, and solid tumors in oncology, such as metastatic triple-negative breast cancer. The company was formerly known as RexRay Corporation. CytoDyn Inc. was incorporated in 2002 and is based in Vancouver, Washington.

www.cytodyn.com

14

Full Time Employees

May 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Recent News

View More

Performance Overview

Trailing total returns as of 10/30/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

CYDY
21.43%
S&P 500 (^GSPC)
10.73%

1-Year Return

CYDY
8.33%
S&P 500 (^GSPC)
11.11%

3-Year Return

CYDY
37.50%
S&P 500 (^GSPC)
81.91%

5-Year Return

CYDY
82.40%
S&P 500 (^GSPC)
64.59%

Earnings Trends

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q3 FY21
Revenue --
Earnings -43.98M
Profit Margin 0.00%

Q4

FY20

Q1

FY21

Q2

FY21

Q3

FY21

-40M
-20M
0
0.0%

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -95.19%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -58.58M

  • Diluted EPS (ttm)

    -0.0300

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    16.36M

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    -9.36M

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: